X

Drug Profile

COTI 219

Alternative Names: COTI-219

Latest Information Update: 03 Sep 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cotinga Pharmaceuticals
Class Antineoplastics; Small molecules
Mechanism of Action KRAS protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer; Colorectal cancer; Small cell lung cancer

Most Recent Events

20 Aug 2024 Preclinical trials in Colorectal cancer in USA (PO) prior to October 2016
20 Aug 2024 Preclinical trials in Small cell lung cancer in USA (PO) prior to October 2016
20 Aug 2024 Critical Outcome Technologies intends to file an IND application with the US FDA for Cancer in 2018

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com